Tissue Regeneration Systems, a biotech spin-out of Michigan and Wisconsin, raises $4.6m from multiple backers including parents.

Biotech Tissue Regeneration Systems (TRS) has received $4.6m in series B funding in a round led by venture firm Venture Investors with participation from the universities of Wisconsin and Michigan.

Founded in 2008 as a collaborative spin-out from the two institutions, TRS is developing research that assists the body in regenerating bone tissue around the face and jaw. Its product is an implantable scaffold which is designed to provide bone-like support while the body reconstructs tissue around it. Over time,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?